Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Innovative health sales up 6% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer               
4Q Revenues: $14.0 billion (+2%)
4Q Loss: $394 million (earnings were $12.3 billion 4Q17)
FY Revenues: $53.6 million (+2%)
FY Earnings: $11.2 billion  (-48%)
Comments: Innovative health sales were $8.9 million in the quarter, up 6% to $5.1 billion. Lyrica sales were up 8% to $1.2 billion in the quarter. Ibrance sales were $1.1 billion, up 58%. Eliquis revenues were $910 million, up 28%. Xeljanz sales were $553 million, up 35%. Prevenar 13 sales were down 1% to $1.5 billion. Enbrel sales were down 17% to $524 million due continued biosimilar competition. Essential health sales were down 4% in the quarter, with 13% operational decline in the Legacy Established Products (LEP) portfolio in developed markets, primarily driven by industry-wide pricing challenges in the U.S. and generic competition; a 14% operational decline in the Sterile Injectable Pharmaceutical (SIP) portfolio in developed markets, primarily due to increased competition across the portfolio and continued legacy Hospira product shortages in the U.S.; and a 10% operational decline in the Peri-LOE Products portfolio in developed markets, primarily due to expected declines in Lyrica in developed Europe and Pristiq.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters